Abstract

The aim of this randomized study was to evaluate potential alterations of the lipid profile and endocrine function in carefully matched healthy female volunteers investigated before and at 6 months’ use of three new oral contraceptives (OCs): Logynon (n=13), a triphasic OC containing low doses of ethinyloestradiol (EE) + levonorgestrel (LNg), Marvelon (n=14), a monophasic OC containing low doses of EE + desogestrel (DOG, a new progestogen derived from LNg) and Ovidol (n=11), a sequential OC containing higher doses (50µg) of EE + DOG.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call